FRAT1 antibody (AA 161-260) (HRP)

Catalog No. ABIN1712053

Product Details anti-FRAT1 Antibody (HRP)

Target: FRAT1 (Frequently Rearranged in Advanced T-Cell Lymphomas (FRAT1))

Binding Specificity: AA 161-260

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This FRAT1 antibody is conjugated to HRP

Application: Western Blotting (WB), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Predicted Reactivity: Human,Mouse,Rat,Dog,Cow

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human FRAT1

Isotype: IgG

Application Details

Application Notes: WB 1:300-5000
IHC-P 1:200-400
IHC-F 1:100-500

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handling Advice: Do NOT add Sodium Azide! Use of Sodium Azide will inhibit enzyme activity of horseradish peroxidase.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for FRAT1

Target: FRAT1 (Frequently Rearranged in Advanced T-Cell Lymphomas (FRAT1))

Alternative Name: FRAT1 (FRAT1 Products)

Background:

Synonyms: FRAT 1, frequently rearranged in advanced T cell lymphomas, Frequently rearranged in advanced T-cell lymphomas, GSK 3 binding protein FRAT1, proto oncogene FRAT1, FRAT1_HUMAN.

Background: FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins.

Gene ID: 10023